Drugs /

incb053914

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor INCB053914 binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.

Clinical Trials

View Clinical Trials for incb053914

Incb053914 has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating incb053914, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open).

Acute myeloid leukemia, diffuse large B-cell lymphoma, and hematopoietic and lymphoid malignancy are the most common diseases being investigated in incb053914 clinical trials [2].

Drug Details

Synonyms [2]:
incb 053914, incb53914, pan-pim kinase inhibitor incb053914, pan-pim kinase inhibitor incb053914, pan-pim inhibitor incb053914
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
PIM1, PIM2, PIM3
NCIT ID [1]:
C124226

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.